Summary
With the object of studying the kinetics of imipramine and desipramine five healthy volunteers received single intramuscular, oral and intravenous doses and multiple oral doses of imipramine hydrochloride on different occasions. Two of the volunteers also received single intramuscular and oral doses of desipramine hydrochloride.
Great interindividual differences were noted in the plasma concentrations of imipramine and the formed desipramine after single doses of imipramine hydrochloride. In all subjects more desipramine was formed after oral than after parenteral administration of imipramine. The bioavailability of an orally administered dose of imipramine ranged between 29.5 and 54.7%. The concentration of imipramine was generally lower in the blood cells than in the plasma, unlike the concentration of desipramine which was considerably higher in the blood cells. The half-lives of imipramine ranged from 4.0–17.6 hrs (M=7.6±2.5) after single oral doses and between 9.2 and 20.2 hrs (M=14.0±1.9) after multiple oral doses. The half-lives of the formed desipramine ranged between 13.5 and 61.5 hrs (M=29.9±8.7) after multiple oral doses of imipramine hydrochloride. The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d., varied from 21.4–69.0 μg/l (M=38.2±8.7) for imipramine and from 33.7–136.0 μg/l (M=72.3±19.5) for desipramine. The great difference in the ability to form desipramine after oral and parenteral administration of imipramine hydrochloride may have therapeutic consequences as imipramine and desipramine have differing pharmacological properties.
Similar content being viewed by others
References
Bickel, M. H., Weder, H. J.: The total fate of a drug: Kinetics of distribution, excretion and formation of 14 metabolites in rats treated with imipramine. Arch. int. Pharmacodyn. 173, 433–463 (1968)
Borgå, O., Palmér, L., Linnarsson, A., Holmstedt, B.: Quantitative determination of nortriptyline and desmethylnortriptyline in human plasma by combined gas chromatography—mass spectrometry. Anal. Letters 4, 837–849 (1971)
Carlsson, A., Corrodi, H., Fuxe, K., Hökfelt, T.: Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alphaethyl-meta-tyramine. Europ. J. Pharmacol. 5, 357–366 (1969 A)
Carlsson, A., Corrodi, H., Fuxe, K., Hökfelt, T.: Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4, alpha-dimethyl-meta-tyramine. Europ. J. Pharmacol. 5, 367–373 (1969 B)
Crammer, J. L., Scott, B., Rolfe, B.: Metabolism of 14C-Imipramine: II Urinary Metabolites in Man. Psychopharmacologia (Berl.) 15, 207–225 (1969)
Davies, P. J., Rabinowitz, R.: Numerical Integration, p. 22. Blaisdell Publishing Company. Waltham, Massachusetts: 1967
Frigerio, A., Belvedere, B., De Nadai, F., Fanelli, R., Pantarotto, C., Riva, E., Morselli, P. L.: A method for the determination of imipramine in human plasma by gas-liquidchromatography-mass fragmentography. J. Chromatogr. 74, 201–208 (1972)
Gibaldi, M., Feldman, S.: Route of administration and drug metabolism. Europ. J. Pharmacol. 19, 323–329 (1972)
Gibaldi, M., Nagashima, R., Levy, G.: Relationship between drug concentration in plasma or serum and amount of drug in the body. J. pharm. Sci. 58, 193–197 (1969)
Hammer, W. M., Brodie, B. B.: Application of isotope derivative technique to assay of secondary amines: Estimation of desipramine by acetylation with H3-acetic anhydride. J. Pharmacol. exp. Ther. 157, 503–508 (1967)
Harris, S. R., Gaudette, L. E., Efron, D. H., Manian, A. A.: A method for the measurement of plasma imipramine and desmethylimipramine concentrations. Life Sci. 9, 781–788 (1970)
Haydu, C. G., Quinor, G. P.: Plasma Imipramine in the Depressions and Psychodynamics. Proc. IV World Congr. Psychiat. Madrid, Sept. 1966 Part 3, Expt. Med. Found. Int. Congr. Ser. No. 150, May 1968
Hillestad, L., Hansen, T., Melsom, H., and Drivenes, A.: Diazepam metabolism in normal man. Clin. Pharmacol. Ther. 16, 479–484 (1974)
Moody, J. P., Tait, A. C., Todrick, A.: Plasma levels of imipramine and desmethyl-imipramine during therapy. Brit. J. Psychiat. 113, 183–193 (1967)
Nagy, A., Treiber, L.: Quantitative determination of imipramine and desipramine in human blood plasma by direct densitometry of thin layer chromatograms. J. Pharm. Pharmacol. 25, 599–603 (1973)
Sjöqvist, F.: A pharmacokinetic approach to the treatment of depression. Int. Pharmacopsychiat. 6, 147–169 (1971)
Wagner, J. G.: Biopharmaceutics and relevant Pharmacokinetics, p. 298. Hamilton, Ill.: Drug Intelligence Publications 1971
Wagner, J. G., Northam, J. I., Alway, C. D., Carpenter, O. S.: Blood levels of drug equilibrium state after multiple dosing. Nature (Lond.) 207, 1301–1302 (1965)
Walter, C. J. S.: Drug plasma levels and clinical effect. Proc. roy Soc. Med. 64, 282–285 (1971)
Åsberg, M., Bertilsson, L., Tuck, D., Cronholm, B., Sjöqvist, F.: Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin. Pharmacol. Ther. 14, 277–286 (1973)
Author information
Authors and Affiliations
Additional information
The results were presented to the Skandinavisk Selskab for Psykofarmakologi (Nagy and Johansson, 1974).
Rights and permissions
About this article
Cite this article
Nagy, A., Johansson, R. Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn-Schmiedeberg's Arch. Pharmacol. 290, 145–160 (1975). https://doi.org/10.1007/BF00510547
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00510547